FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB AP	PROVAL
OMB Number:	3235-0

OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Vukovic Vojo</u>					2. Issuer Name and Ticker or Trading Symbol AILERON THERAPEUTICS INC [ALRN]					(Cho	eck all applic	able)	Person(s) to Iss	vner	
(Last) (First) (Middle) C/O AILERON THERAPEUTICS, INC. 490 ARSENAL WAY					3. Date of Earliest Transaction (Month/Day/Year) 04/15/2019						Officer (give title below) SVP, Chief Medical Officer			specify	
(Street) WATERTOWN MA 02472 (City) (State) (Zip)				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line) X Form fil Form fil	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person			
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D					action 2A. Deemed Execution Date,		3. Transaction Code (Instr. 8) 3. 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4)		red (A) or str. 3, 4 and	5. Amour Securities Beneficia Owned For	s Illy ollowing (I	Form: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Table II - Derivati (e.g., p.								uired, Dis	posed o	f, or Ben	eficially	Owned			
1. Title of Derivative Security (Instr. 3)	2. Conversio or Exercis Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	1(5)	
Stock Option (right to buy)	\$1.75	04/15/2019		A		100,000		(1)	04/14/2029	Common Stock	100,000	\$0.00	100,000	D	

Explanation of Responses:

1. This option was granted on April 15, 2019. The shares underlying the option are scheduled to vest in equal monthly installments over four years from April 15, 2019.

Remarks:

/s/ Donald Dougherty, attorney-04/17/2019 in-fact for Vojo Vukovic

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.